Biotech RadarJobs updated

COMPANY

Vertex Pharmaceuticals Incorporated

HQ: Boston, MA source

FDA-approved therapeutic company Clinical Phase 3

Also known as Vertex Pharmaceuticals · 324 open jobs · last seen Oct 21, 2026 · 51 sources

Profile checked Oct 10, 2026

Keywords: Autosomal Dominant Polycystic Kidney Disease Cystic Fibrosis Sickle Cell Disease Hemoglobinopathies Diabetic Peripheral Neuropathic Pain Beta-Thalassemia Thalassemia Hematologic Diseases Inborn Genetic Diseases Acute Pain Proteinuric Kidney Disease Hematological Diseases Type 1 Diabetes Myotonic Dystrophy Type 1 (DM1) Sickle Cell Anemia Immunoglobulin A Nephropathy Primary Membranous Nephropathy Generalized Myasthenia Gravis Type 1 Diabetes Mellitus Impaired Hypoglycemic Awareness Severe Hypoglycemia Hydroxyurea Failure Hydroxyurea Intolerance Narcolepsy Type 1 (NT1) Kidney Transplant Painful Lumbosacral Radiculopathy VX-407 Suzetrigine CTX001 Povetacicept VX-581 Exa-cel VX-121/TEZ/D-IVA VX-670 VX-828 VX-993 VX-272 VX-147 VX-264

324Open jobs247Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Azure DevOps EngineerBoston, MANot statedOct 21, 2026
Project Management Associate DirectorBoston, MANot statedOct 21, 2026
Industrial Placement Student - Regulatory Affairs (12 months)Paddington, United KingdomNot statedOct 21, 2026
Spring Co-Op 2027, Commercial AnalyticsBoston, MANot statedOct 21, 2026
Vertex Summer Intern, Legal (10 weeks)Paddington, United KingdomNot statedOct 21, 2026

See all 324 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Trial start Phase 3: Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype source ↗
  2. Board tracked Radar started tracking this company’s job board (324 open jobs at last check). source ↗
  3. Trial start 3: A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy source ↗
  4. Trial start 1: A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation source ↗
  5. Trial start Phase 1: Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives source ↗
  6. Trial start 1: A Phase 1, First-in-human Study of VX-433 source ↗
  7. Trial start 2: A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis source ↗
  8. Trial start Phase 1: Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants source ↗
  9. Trial start Phase 4: Evaluation of Pain Treatment After Total Knee Arthroplasty source ↗
  10. Trial start Phase 1: Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants source ↗
  11. Trial start Phase 1: Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants source ↗
  12. Trial start Phase 1: Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants source ↗
  13. Trial start Phase 1: Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants source ↗
  14. Trial start Phase 3: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy source ↗
  15. Trial start 2: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) source ↗
  16. Trial start Phase 2/Phase 3: Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) source ↗
  17. Trial start Phase 1: Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants source ↗
  18. Trial start 1: A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants source ↗
  19. Trial start Phase 2: A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I source ↗
  20. Trial start Phase 3: An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant source ↗
  21. Trial start Phase 4: A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries source ↗
  22. Trial start Phase 4: A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries source ↗
  23. Trial start Phase 2: Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities source ↗
  24. Trial start —: Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease source ↗
  25. Trial start Phase 3: Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) source ↗

Showing 25 of 51 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 324

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Azure DevOps EngineerBoston, MANot statedOct 21, 2026Not stated
Project Management Associate DirectorBoston, MANot statedOct 21, 2026Not stated
Industrial Placement Student - Regulatory Affairs (12 months)Paddington, United KingdomNot statedOct 21, 2026Not stated
Spring Co-Op 2027, Commercial AnalyticsBoston, MANot statedOct 21, 2026Not stated
Vertex Summer Intern, Legal (10 weeks)Paddington, United KingdomNot statedOct 21, 2026Not stated
Legal InternParis, FranceNot statedOct 21, 2026Not stated
Summer Intern, Regulatory Affairs (10 weeks)Paddington, United KingdomNot statedOct 21, 2026Not stated
Data Governance Associate DirectorBoston, MANot statedOct 21, 2026Not stated
Spring 2027 Co-op, Internal AuditBoston, MANot statedOct 21, 2026Not stated
Spring 2027 Co-op, Performance Excellence and Business TransformationBoston, MANot statedOct 21, 2026Not stated
Materials Management Warehouse Senior SpecialistBoston, MANot statedOct 21, 2026Not stated
Commercial Training Senior Manager — Field Reimbursement, Patient ServicesBoston, MANot statedOct 21, 2026Not stated
GCP Operational Quality Associate DirectorBoston, MANot statedOct 21, 2026Not stated
Structural Biology & Biophysics - Industrial Placement (12 Months)Oxford, United KingdomNot statedOct 21, 2026Not stated
Early Development Associate Medical DirectorBoston, MANot statedOct 21, 2026Not stated
Vertex Summer Intern, Commercial (10 weeks)Paddington, United KingdomNot statedOct 21, 2026Not stated
Vertex Summer Intern, International Supply Chain (10 weeks)Paddington, United KingdomNot statedOct 21, 2026Not stated
UK and Ireland Marketing Industrial Placement (12 Months)Paddington, United KingdomNot statedOct 21, 2026Not stated
Senior Director, DMPKSan Diego, CANot statedOct 18, 2026Not stated
Medicinal Chemistry Senior Principal Research ScientistSan Diego, CANot statedOct 18, 2026Not stated
Senior Director, Innovation & Business TransformationBoston, MANot statedOct 18, 2026Not stated
Market Access and Analytics Associate DirectorBoston, MANot statedOct 18, 2026Not stated
Rebate Operations ManagerBoston, MANot statedOct 18, 2026Not stated
Senior Regional Sales Director, West RegionTexas - Field BasedNot statedOct 18, 2026Not stated
Accounting ManagerPaddington, United KingdomNot statedOct 18, 2026Not stated
Spring Co-Op 2027, In Silico ModelingBoston, MANot statedOct 18, 2026Not stated
Spring Co-Op 2027, Commercial Analytics, Market AccessBoston, MANot statedOct 18, 2026Not stated
Director, Commercial Data Strategy & EnablementBoston, MANot statedOct 18, 2026Not stated
Innovation & Business Transformation, Associate DirectorBoston, MANot statedOct 18, 2026Not stated
Innovation & Business Transformation, Sr. ManagerBoston, MANot statedOct 18, 2026Not stated
Distributor Marketing Industrial Placement (12 Months)Paddington, United KingdomNot statedOct 18, 2026Not stated
Supply Chain Industrial Placement (12 months)Paddington, United KingdomNot statedOct 15, 2026Mid
Director, Project Management & Strategic Operations (Disease Strategy Team)Boston, MANot statedOct 15, 2026Senior
Senior Mechanical Engineer IISan Diego, CANot statedOct 15, 2026Senior
Senior Director, US Patient Support Affordability Strategy & ProgramsBoston, MANot statedOct 15, 2026Senior
Pain Regional Field Sales Leader - South Florida Territory2 locations, including Field Based, United StatesNot statedOct 15, 2026Senior
Associate Director, Small Molecules & Biologics Logistics Operations (Remote Eligible)Boston, MANot statedOct 15, 2026Senior
Marketing Senior ManagerSao Paulo, BrazilNot statedOct 15, 2026Senior
Summer Intern, Commercial HaematologyPaddington, United KingdomNot statedOct 15, 2026Entry
Real World Principal Biostatistician2 locations (listed on the posting)Not statedOct 15, 2026Senior
Pain Regional Field Sales Leader - Blue Grass Territory (Kentucky/Indiana/Ohio)4 locations, including Field Based, United StatesNot statedOct 15, 2026Senior
Medical Device & Combination Product Development, Associate DirectorBoston, MANot statedOct 15, 2026Senior
Senior Manager, Procurement Master Data & AnalyticsBoston, MANot statedOct 15, 2026Senior
Director, Commercial Quality-Packaging and LabelingBoston, MANot statedOct 15, 2026Senior
Commercial Haematology Industrial Placement (12 Months)Paddington, United KingdomNot statedOct 15, 2026Mid
Commercial Nephrology Industrial Placement (12 Months)Paddington, United KingdomNot statedOct 15, 2026Mid
DMQ Quality GraduatePaddington, United KingdomNot statedOct 12, 2026Entry
Spring 2027 Co-op, Exploratory BiologyBoston, MANot statedOct 10, 2026Entry
Field Communications Senior ManagerUnited States - Field BasedNot statedOct 10, 2026Senior
Publications Science Director, EndocrinologyBoston, MANot statedOct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 324 jobs →

Clinical trials (lead sponsor) Showing 50 of 247

RecordTitlePhaseStatusStartPrimary completion
NCT07807995A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy3Enrolling by invitationSep 17, 2026Dec 28, 2029 (estimated)
NCT07792408Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesPhase 1RecruitingSep 1, 2026Mar 11, 2027 (estimated)
NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsPhase 1RecruitingFeb 25, 2026Jun 26, 2027 (estimated)
NCT07161037Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)2Active, not recruitingNov 19, 2025Jul 22, 2027 (estimated)
NCT05312879Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease2RecruitingMar 30, 2022Jun 2, 2028 (estimated)
NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsPhase 1RecruitingDec 9, 2025Nov 19, 2026 (estimated)
NCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Phase 2/Phase 3RecruitingSep 30, 2025Dec 29, 2028 (estimated)
NCT03745287A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseasePhase 2/Phase 3CompletedNov 27, 2018Jul 7, 2025 (actual)
NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis2RecruitingMay 13, 2026Mar 2, 2029 (estimated)
NCT05791201A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesPhase 1/Phase 2Active, not recruitingMay 16, 2023Mar 12, 2027 (estimated)
NCT07813039A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation1Not yet recruitingSep 7, 2026Oct 27, 2026 (estimated)
NCT05444257A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyPhase 3Active, not recruitingNov 8, 2022Oct 30, 2026 (estimated)
NCT05331183Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delPhase 3Active, not recruitingNov 23, 2022Apr 6, 2027 (estimated)
NCT07378865Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female ParticipantsPhase 1CompletedFeb 13, 2026Aug 17, 2026 (actual)
NCT06747572Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseNot listedActive, not recruitingDec 19, 2024Dec 31, 2026 (estimated)
NCT05668741A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)1Active, not recruitingFeb 27, 2023Apr 21, 2026 (actual)
NCT06696443Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Phase 3Active, not recruitingDec 18, 2024Jan 25, 2027 (estimated)
NCT04786262A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesPhase 3RecruitingMar 29, 2021Dec 31, 2027 (estimated)
NCT06185764A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)1Active, not recruitingFeb 20, 2024Feb 2, 2027 (estimated)
NCT06794996Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesPhase 2CompletedFeb 4, 2025Jul 20, 2026 (actual)
NCT07570069Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy ParticipantsPhase 1CompletedMay 7, 2026Jul 16, 2026 (actual)
NCT07538570Evaluation of Pain Treatment After Total Knee ArthroplastyPhase 4RecruitingApr 24, 2026Jan 30, 2027 (estimated)
NCT04208529A Long-term Follow-up Study in Participants Who Received CTX001Phase 3Enrolling by invitationJan 20, 2021Sep 30, 2039 (estimated)
NCT06154447Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisPhase 1CompletedDec 12, 2023Jul 10, 2026 (actual)
NCT06926621A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IPhase 2Enrolling by invitationApr 28, 2025Jan 30, 2029 (estimated)
NCT07231419Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyPhase 3RecruitingNov 21, 2025Apr 6, 2027 (estimated)
NCT05356195Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Phase 3Active, not recruitingMay 3, 2022Nov 14, 2027 (estimated)
NCT05329649Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Phase 3Active, not recruitingMay 2, 2022Jun 6, 2027 (estimated)
NCT06628908Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPhase 3RecruitingOct 1, 2024May 31, 2027 (estimated)
NCT07584434A Phase 1, First-in-human Study of VX-4331RecruitingMay 21, 2026Mar 5, 2027 (estimated)
NCT06460506Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderPhase 3Active, not recruitingNov 21, 2024Sep 30, 2027 (estimated)
NCT06619860Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyPhase 2RecruitingOct 18, 2024Mar 25, 2027 (estimated)
NCT05422222Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgePhase 3Active, not recruitingJun 21, 2022Jun 30, 2030 (estimated)
NCT06619847A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a BunionectomyPhase 2CompletedOct 29, 2024May 27, 2025 (actual)
NCT05844449Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and OlderPhase 3Enrolling by invitationAug 11, 2023Jul 30, 2029 (estimated)
NCT07349394Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy ParticipantsPhase 1CompletedJan 12, 2026Feb 28, 2026 (actual)
NCT07074327Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy ParticipantsPhase 1CompletedJul 11, 2025Feb 20, 2026 (actual)
NCT07022119A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants1CompletedJun 12, 2025Feb 24, 2026 (actual)
NCT05951205Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC GenotypePhase 3WithdrawnJul 31, 2027Dec 31, 2033 (estimated)
NCT05477563Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseasePhase 3RecruitingAug 2, 2022Jun 9, 2027 (estimated)
NCT06832410An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantPhase 3RecruitingMar 31, 2025Sep 17, 2026 (estimated)
NCT05153317Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderPhase 3CompletedJan 17, 2022Jan 29, 2026 (actual)
NCT06506773Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)Not listedCompletedJul 9, 2024Nov 27, 2025 (actual)
NCT03655678A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaPhase 2/Phase 3CompletedSep 14, 2018Nov 13, 2025 (actual)
NCT06887972A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive SurgeriesPhase 4CompletedMar 21, 2025Oct 24, 2025 (actual)
NCT06887959A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected SurgeriesPhase 4CompletedMar 27, 2025Oct 27, 2025 (actual)
NCT05882357Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgePhase 3CompletedJun 27, 2023Sep 4, 2025 (actual)
NCT06176196Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)Phase 2CompletedDec 13, 2023Oct 2, 2024 (actual)
NCT06299709A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)Phase 1CompletedMar 13, 2024May 23, 2024 (actual)
NCT03525574A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyPhase 3CompletedOct 9, 2018Jan 9, 2023 (actual)
Feedback